Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,397 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Genentech, Inc. Clear all
Completed Phase 2 Interventional

Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

NCT03071055
View directory record Official record
Conditions
Exudative Age Related Macular Degeneration
Interventions
Ranibizumab Injection [Lucentis]
Drug
Lead sponsor
Southeast Clinical Research Associates, LLC
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Charlotte, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 26, 2026, 2:20 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

NCT03332797
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-9545, Palbociclib, LHRH Agonist
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

NCT00834678
View directory record Official record
Conditions
Breast Cancer
Interventions
bendamustine, erlotinib, Maintenance erlotinib
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 4 Interventional Results available

A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

NCT02392624
View directory record Official record
Conditions
Urticaria
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
40
States / cities
Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Rituximab in Neuromyelitis Optica

NCT00501748
View directory record Official record
Conditions
Neuromyelitis Optica
Interventions
Rituximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 86 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
San Francisco, California • Columbia University Medical Center 710 West 168th Street,, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers

NCT01423318
View directory record Official record
Conditions
Healthy Volunteer
Interventions
lebrikizumab, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 26, 2026, 2:20 PM EDT
Withdrawn Phase 1 Interventional

A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

NCT05961696
View directory record Official record
Conditions
Refractory B-cell Acute Lymphoblastic Leukemia
Interventions
Mosunetuzumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Study of Tocilizumab to Treat Polymyalgia Rheumatica

NCT01396317
View directory record Official record
Conditions
Polymyalgia Rheumatica (PMR)
Interventions
Tocilizumab
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer

NCT00365417
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, Doxorubicin, Cyclophosphamide, Capecitabine, Docetaxel
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 26, 2026, 2:20 PM EDT
Active, not recruiting No phase listed Observational

An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

NCT05300724
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
No intervention
Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 94 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
46
States / cities
Springdale, Arkansas • Encino, California • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 26, 2026, 2:20 PM EDT
Terminated Phase 4 Interventional Results available

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

NCT02353780
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi), Abatacept, Tocilizumab
Drug
Lead sponsor
Dr. Larry W. Moreland
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Dosing Interval of Higher Doses of Ranibizumab

NCT00533520
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
ranibizumab
Drug
Lead sponsor
Brandon G. Busbee, MD
Other
Eligibility
50 Years to 95 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants

NCT06690138
View directory record Official record
Conditions
Healthy Participants
Interventions
Divarasib, Itraconazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 26, 2026, 2:20 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

NCT01108458
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pertuzumab, Erlotinib
Drug
Lead sponsor
George Albert Fisher
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)

NCT00304278
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Erlotinib (Tarceva), Intra-arterial Cisplatin (PLAT), Radiation Therapy (RAD)
Drug · Radiation
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage

NCT02300025
View directory record Official record
Conditions
Healthy Volunteer
Interventions
cobimetinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

NCT05867121
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
RO7496353, Atezolizumab, Capecitabine, S-1, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 26, 2026, 2:20 PM EDT
Terminated Not applicable Interventional Results available

Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density

NCT00145704
View directory record Official record
Conditions
Osteopenia
Interventions
bisphosphonate therapy (risedronate), Vitamin D supplement, Calcium
Drug · Dietary Supplement
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 26, 2026, 2:20 PM EDT
Terminated Phase 1 Interventional Results available

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT03136497
View directory record Official record
Conditions
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
400mg ABT-199, Ibrutinib, Rituximab, 800mg ABT-199
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer

NCT00548418
View directory record Official record
Conditions
Cervical Cancer
Interventions
Topotecan, Cisplatin, Bevacizumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
St Louis, Missouri • Durham, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Not applicable Interventional

A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia

NCT02619604
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Education Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

NCT01476449
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
2
States / cities
Clearwater, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 1 Interventional

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

NCT00765921
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
ranibizumab
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 26, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and ABVD for Hodgkin's Patients

NCT00504504
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Adriamycin, Bleomycin, Vinblastine, Dacarbazine (DTIC)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 26, 2026, 2:20 PM EDT